Atugen Pens Gene Validation Deal with OGS | GenomeWeb

NEW YORK, Dec. 11 - Atugen of Berlin said Tuesday it had signed a deal to validate gene targets for Oxford GlycoSciences.

Under the terms of the deal, OGS of Oxford, UK, will provide targets to Atugen, which will validate them using its animal models.

Atugen has developed a technology called GeneBloc, which is designed to block protein production, enabling the company to determine gene function.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.